Blair William & Co. IL Decreases Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Key Points

• Blair William & Co. IL reduced its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 17.1%, selling 24,594 shares and now holding approximately 118,882 shares valued at $2.31 million.
• Several other institutional investors also adjusted their positions, with Alliancebernstein L.P. increasing its holdings by 109.7% during the same period.
• Cellebrite DI reported a 20% increase in revenue year-over-year, with a quarterly earnings per share (EPS) of $0.10, exceeding analyst expectations.

Blair William & Co. IL lowered its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 17.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 118,882 shares of the company's stock after selling 24,594 shares during the quarter. Blair William & Co. IL's holdings in Cellebrite DI were worth $2,310,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. US Bancorp DE bought a new position in shares of Cellebrite DI during the 1st quarter worth about $308,000. Natixis Advisors LLC bought a new position in shares of Cellebrite DI during the 1st quarter worth about $469,000. XTX Topco Ltd boosted its position in shares of Cellebrite DI by 37.2% during the 1st quarter. XTX Topco Ltd now owns 35,095 shares of the company's stock worth $682,000 after purchasing an additional 9,518 shares in the last quarter. TD Asset Management Inc boosted its position in shares of Cellebrite DI by 909.6% during the 1st quarter. TD Asset Management Inc now owns 106,306 shares of the company's stock worth $2,066,000 after purchasing an additional 95,777 shares in the last quarter. Finally, Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD boosted its position in shares of Cellebrite DI by 9.2% during the 1st quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 380,081 shares of the company's stock worth $7,381,000 after purchasing an additional 31,908 shares in the last quarter. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Performance

NASDAQ:CLBT traded up $0.39 on Tuesday, hitting $13.91. The stock had a trading volume of 1,970,416 shares, compared to its average volume of 1,567,745. The stock has a market cap of $3.33 billion, a P/E ratio of -14.49, a price-to-earnings-growth ratio of 2.74 and a beta of 1.27. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The firm's fifty day simple moving average is $15.14 and its two-hundred day simple moving average is $17.99.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The company had revenue of $107.55 million during the quarter, compared to analyst estimates of $109.36 million. During the same quarter last year, the business posted $0.08 EPS. Cellebrite DI's quarterly revenue was up 20.0% compared to the same quarter last year. Equities research analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CLBT. JPMorgan Chase & Co. cut their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, May 12th. Wall Street Zen cut shares of Cellebrite DI from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price target on shares of Cellebrite DI in a research report on Friday, June 6th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $22.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.